Expression of apoptosis-related proteins and response to chemoradiotherapy and prognosis in esophageal cancer

Clinical and Translational Oncology

Volumn 2, Issue 3, 2000, Pages 146-153

  Font, Albert ^a   Rigas, James R ^b   Eastman, Alan ^b   Memoli, Vincent A ^b   Cole, Bernard F ^b   Hammond, Sue ^b   Rosell, Rafael ^a  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

Apoptosis related proteins; Chemoradiotherapy; Esophageal cancer; Prognostic marker

Indexed keywords

EID: 79956071862     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Forastiere AA, Heitmiller RF and Kleinberg L. Multimodality therapy for esophageal cancer. Chest 1997; 112 (Supl): 195-200.
2. Walsh TN, Noonan N, Hollywood D, Kelly A, Keeling N, Hennessy TPJ. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med 1996; 335: 462-467.
3. Bosset JF, Gignoux M, Triboulet JP, Tiret E, Mantinon G, Elias D et al. Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med 1997; 337: 161-167.
4. Krajewski S, Thor AD, Edgerton SM, Moore DH, Krajewska TM, Reed JC. Analysis of Bax and Bcl-2 expression in p53-immunopositive breast cancers. Clin Cancer Res 1997; 3: 199-208.
5. Herod JJ, Eliopoulos AG, Warwick J, Niedobitek G, Young LS, Kerr DJ. The prognostic significance of Bcl-2 and p53 expression in ovarian carcinoma. Cancer Res 1996; 56: 2178-2184.
6. Pezzella F, Turley H, Kuzu I, Tungekar MF, Dunnill MS, Pierce CB et al. Bcl-2 protein in non-small-cell lung carcinoma. N Engl J Med 1993; 329: 690-694.
7. Bonetti A, Zaninelli M, Leone R, Cetto GL, Pelosi G, Biolo S et al. Bcl-2 but not p53 expression is associated with resistance to chemotherapy in advanced breast cancer. Clin Cancer Res 1998; 4: 2331-2336.
8. Gallo O, Boddi V, Calzolari A, Simonetti L, Trovati M, Bianchi S. Bcl-2 protein expression correlates with recurrence and survival in early stage head and neck cancer treated by radiotherapy. Clin Cancer Res 1996; 2: 261-267.
9. Borre M, Stausbol-Gron B, Nerstrom B, Overgaard J. Immunohistochemical BCL-2 and Ki-67 expression predict survival in prostate cancer patients followed expectantly. Prostate Cancer and Prostatic Diseases 1998; 5: 268-275.
10. Krajewski S, Blomqvist C, Franssila K, Krajewska M, Wasenius VM, Niskanen E et al. Reduced expression of proapoptotic gene BAX is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma. Cancer Res 1995; 55: 4471-4478.
11. Tai YT, Lee S, Niloff E, Weisman C, Strobel T, Cannistra SA. BAX protein expression and clinical outcome in epithelial ovarian cancer. J Clin Oncol 1998; 16: 2583-2590.
12. Ohbu M, Saegusa M, Kobayashi N, Tsukamoto H, Mieno H, Kakita A et al. Expression of bcl-2 protein in esophageal squamous cell carcinomas and its association with lymph node metastasis. Cancer 1997; 79: 1287-1293.
13. Puglisi F, Di Loreto C, Panizzo R, Avellini C, Fongione S, Cacitti V et al. Expression of p53 and bcl-2 and response to preoperative chemotherapy and radiotherapy for locally advanced squamous cell carcinoma of the oesophagus. J Clin Pathol 1996; 49: 456-459.
14. Patel DD, Bhatavdekar JM, Chikhlikar PR, Patel YV, Shah NG, Ghosh N et al. Clinical significance of p53, nm23 and bcl-2 in T3-4N1M0 oesophageal carcinoma: an immunohistochemical approach. J Surg Oncol 1997; 65: 111-116.
15. Sarbia M, Stahl M, Fink U, Willers R, Seeber S, Gabbert HE. Expression of apoptosis-regulating proteins and outcome of esophageal cancer patients treated by combined therapy modalities. Clin Cancer Res 1998; 4: 2991-2997.
16. Urba S, Orringer M, Turrisi A, Whyte R, Iannettoni M, Forastiere A. A randomized trial comparing surgery to preoperative concomitant chemoradiation plus surgery in patients with resectable esophageal cancer: updated analysis. Proc Am Soc Clin Oncol 1997; 16: 277.
17. Herskovic A, Martz K, Al-Sarraf M, Leichman L, Brindle J, Vaitkevicius V et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med 1992; 326: 1593-1598.
18. Torzewski M, Sarbia M, Heep H, Dutkowski P, Willers R, Gabbert HE. Expression of Bcl-XL, an antiapoptotic member of the Bcl-2 family, in esophageal squamous cell carcinoma. Clin Cancer Res 1998; 4: 577-583.
19. Ofner D, Riehemann K, Maier H, Reidmann B, Nehoda H, Totsch M et al. Immunohistochemically detectable bcl-2 expression in colorectal carcinoma: correlation with tumor stage and patient survival. Br J Cancer 1995; 72: 981-985
20. Sarbia M, Bittinger F, Porschen R, Verreet P, Dutkowski P, Willers R et al. Bcl-2 expression and prognosis in squamous cell carcinomas of the esophagus. Int J Cancer 1996; 69: 324-328.
21. Sarbia M, Bittinger F, Grabellus F, Verreet P, Dutkowski P, Willers R et al. Expression of bax, a proapoptotic member of the bcl-2 family, in esophageal squamous cell carcinoma. Int J Cancer 1997; 73: 508-513.
22. Apolinario RM, Van der Valk P, De Jong JS, Deville W, Van Ark-Otte J, Dingemans AMC et al. Prognostic value of the expression of p53, bcl-2 and bax oncoproteins, and neovascularization in patients with radically resected non-small cell lung cancer. J Clin Oncol 1997; 15: 2456-2466.
23. Miyashita T, Reed JC. Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood 1993; 81: 151-157.
24. Tu Y, Renner S, Xu FH, Fleishman A, Taylor J, Weisz J et al. BCL-X expression in multiple myeloma: Possible indicator of chemoresistance. Cancer Res 1998; 58: 256-262.
25. Strobel T, Kraeft SK, Chen LB, Cannistra SA. BAX expression is associated with enhanced intracellular accumulation of paclitaxel: a novel role for BAX during chemotherapy-induced cell death. Cancer Res 1998; 58: 4776-4781.
26. Strobel T, Tai YT, Korsmeyer S, Cannistra SA. BAD partly reverses paclitaxel resistance in human ovarian cancer cell. Oncogene 1998; 17: 2419-2427.
27. Escuin D, Rosell R. The anti-apoptosis survivin gene and its role in human cancer: an overview. Clinical Lung Cancer 1999; 1: 138-143.
28. Singh KK, Russell J, Scigala B, Zhang Y, Williams J, Keshar KF. Mitochondrial DNA determines the cellular response to cancer therapeutic agents. Oncogene 1999; 18: 6641-6646.
29. Murphy KM, Satreips UN, Lock RB. Bax membrane insertion during Fas (CD95)-induced apoptosis precedes cytochrome c release and is inhibited by Bcl-2. Oncogene 1999; 18: 5991-5999.
30. Bairey O, Zimra Y, Shaklai M, Okon E, Rabizadeh E. Bcl-2, Bcl-X, Bax and Bak expression in short- and long-lived patients with diffuse large B-cell lymphomas. Clin Cancer Res 1999; 5: 2860-2866.